94 related articles for article (PubMed ID: 20298123)
1. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
Hvas CL; Kelsen J; Agnholt J; Dige A; Christensen LA; Dahlerup JF
Autoimmunity; 2010 Jun; 43(4):325-33. PubMed ID: 20298123
[TBL] [Abstract][Full Text] [Related]
2. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.
Toubi E; Kessel A; Mahmudov Z; Hallas K; Rozenbaum M; Rosner I
Ann N Y Acad Sci; 2005 Jun; 1051():506-14. PubMed ID: 16126991
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
[TBL] [Abstract][Full Text] [Related]
4. [Expression of CD4+ CD25+ regulatory T cells in peripheral blood and salivary gland of patients with primary Sjögren's syndrome].
Li XM; Li XP; Qian L; Wang GS; Zhang H; Zhei ZM; Li Q; Chen K; Wang XQ; Wang YP
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1034-6. PubMed ID: 17672966
[TBL] [Abstract][Full Text] [Related]
5. [Study on expressions of CD25 and CD127 in CD4+ peripheral T lymphocytes of patients with rheumatoid arthritis].
Huang ZX; Zheng BR; Li TW; Lu YM; Gu JR; Han XY
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2476-80. PubMed ID: 20137434
[TBL] [Abstract][Full Text] [Related]
6. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
[TBL] [Abstract][Full Text] [Related]
7. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab.
Di Sabatino A; Saarialho-Kere U; Buckley MG; Gordon JN; Biancheri P; Rovedatti L; Corazza GR; Macdonald TT; Pender SL
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1049-55. PubMed ID: 19357521
[TBL] [Abstract][Full Text] [Related]
8. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
9. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease.
Ferkolj I; Ihan A; Markovic S; Veceric Z; Pohar M
J Gastrointestin Liver Dis; 2006 Sep; 15(3):231-5. PubMed ID: 17013447
[TBL] [Abstract][Full Text] [Related]
10. Low circulating regulatory T-cell levels after acute rejection in liver transplantation.
Demirkiran A; Kok A; Kwekkeboom J; Kusters JG; Metselaar HJ; Tilanus HW; van der Laan LJ
Liver Transpl; 2006 Feb; 12(2):277-84. PubMed ID: 16447185
[TBL] [Abstract][Full Text] [Related]
11. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
12. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
Balanescu A; Radu E; Nat R; Regalia T; Bojinca V; Ionescu R; Balanescu S; Savu C; Predeteanu D
Int J Clin Pharmacol Res; 2005; 25(1):9-18. PubMed ID: 15864873
[TBL] [Abstract][Full Text] [Related]
13. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation.
Wang Z; Xiao L; Shi BY; Qian YY; Bai HW; Chang JY; Cai M
Transpl Immunol; 2008 Apr; 19(1):69-73. PubMed ID: 18346640
[TBL] [Abstract][Full Text] [Related]
14. Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28.
Sempere-Ortells JM; Pérez-García V; Marín-Alberca G; Peris-Pertusa A; Benito JM; Marco FM; Zubcoff JJ; Navarro-Blasco FJ
Autoimmunity; 2009; 42(8):636-45. PubMed ID: 19886735
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
16. Short-term study of infliximab treatment for Crohn's disease in China.
Zheng JJ; Zhi P; Wang YM; Zhu F; Gu W; Xing YC; Zhou CL; Shen BW
J Dig Dis; 2011 Apr; 12(2):105-9. PubMed ID: 21401895
[TBL] [Abstract][Full Text] [Related]
17. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.
Kavousanaki M; Makrigiannakis A; Boumpas D; Verginis P
Arthritis Rheum; 2010 Jan; 62(1):53-63. PubMed ID: 20039433
[TBL] [Abstract][Full Text] [Related]
18. A dual action of rheumatoid arthritis synovial fibroblast IL-15 expression on the equilibrium between CD4+CD25+ regulatory T cells and CD4+CD25- responder T cells.
Benito-Miguel M; García-Carmona Y; Balsa A; Pérez de Ayala C; Cobo-Ibáñez T; Martín-Mola E; Miranda-Carús ME
J Immunol; 2009 Dec; 183(12):8268-79. PubMed ID: 20007590
[TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
Eivindson M; Grønbaek H; Skogstrand K; Thorsen P; Frystyk J; Flyvbjerg A; Dahlerup JF
Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
[TBL] [Abstract][Full Text] [Related]
20. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus.
Lee HY; Hong YK; Yun HJ; Kim YM; Kim JR; Yoo WH
Rheumatology (Oxford); 2008 Jun; 47(6):789-94. PubMed ID: 18388146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
